Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants

NCT ID: NCT03613987

Last Updated: 2023-03-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-26

Study Completion Date

2022-07-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infants delivered weighing less than 1 kg at birth (ELBW) are at high risk for the development of bronchopulmonary dysplasia (BPD) and Ventilator-Induced Lung Injury (VILI), in part because of the need for mechanical ventilation utilizing an endotracheal tube (MVET). In spite of strategies to minimize the need for MVET, the incidence of BPD in ELBW infants continues to be 20-80%. The hypothesis is that synchronized NIPPV will decrease the need for MVET and reduce BPD in ELBW infants as compared to NIPPV.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypothesis:

The hypothesis is that sNIPPV will decrease the need for MVET and reduce BPD in ELBW infants as compared to NIPPV.

Specific Aims:

The specific aims are to determine whether:

1. sNIPPV results in a decreased need for MVET at 7days of life and 28 days of life in ELBW infants compared to NIPPV.
2. sNIPPV reduces BPD in ELBW infants compared to NIPPV. Research design and methods: ELBW infants will be enrolled in this study at the RNICU at MFCH of WMC following informed written parental consent.

Randomization:

ELBW infants will be randomized to either sNIPPV group or NIPPV group using a computer-generated scheme.

Extubation criteria:

1. Infant is receiving caffeine.
2. Infants can be extubated at any point, but must be extubated following a 12-hour period of clinical stability when the ventilator settings have met all the following criteria:

* mean airway pressure (MAP) \< 8cmH20,
* FiO2 \< 0.4,
* pH \> 7.2, and
* pCO2 \< 70.

Intubation criteria:

Infants must be intubated if any of the following criteria occur:

1. One apneic event requiring positive pressure ventilation (PPV).
2. More than 6 apneic events requiring stimulation within a 6-hour period.
3. A deterioration in respiratory status as noted by any of the following criteria:

* pH \< 7.2,
* pCO2 \> 70,
* FiO2 \> 0.6,
4. Or, if in the opinion of the attending neonatologist, the baby is failing either non-invasive strategy.

Data Collection:

Demographic and outcome data will be collected from source data, and then the patient will be given a unique identifier, without reference to MRN or birthdate.

Tracheal aspirates will be collected per routine nursing care to look for inflammatory cytokine markers (IL8, IL6 and TNF alpha). This may help to determine if certain infants remained intubated due to a pro-inflammatory mechanism (if their TA cytokines were elevated early compared to those who may have been more successfully extubated because of low levels of cytokines).

During hospital stay, DNA and RNA samples will be extracted from buccal swabs, as certain babies are more susceptible to BPD based on their genetic foundations.

Charts will be reviewed to determine the duration of oxygen therapy as well as the duration of MVET.

MVET will be assessed at 7 days of life and 28 days of life as primary outcome. BPD, as defined as oxygen requirement at 36 weeks PMA, is a secondary outcome. Initial statistical analysis will be performed using chi square for categorical data; and t-test or Mann Whitney for continuous data that is normally or non-normally distributed (respectively), with statistical significance when P \< 0.05.

Power analysis:

Based on the investigators' NICU data that NIPPV has MVET rate at 7 days of life of 84% for ELBWs, it was hypothesized that sNIPPV will decrease the need for MVET at 7 days of life by 40%. For a power of 80%, and an alpha value of 0.05, the sample size is 27 infants in each group. Anticipating a 10% dropout rate, this gives 30 as the sample size for each group.

Anticipated timeline:

With 80-100 ELBW infants admitted each year, enrollment is anticipated to be completed in 1 year.

The clinical implications of this study will determine if synchronized NIPPV in ELBW infants will reduce the need for mechanical ventilation and ultimately BPD.

There are no procedures, situations, or materials that will be hazardous to personnel. There are no courses planned which support the research training experience. This research will not include the use of experimental drugs or treatments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

BPD - Bronchopulmonary Dysplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NIPPV

non synchronized non invasive positive pressure ventilation

Group Type NO_INTERVENTION

No interventions assigned to this group

NAVA-NIPPV

synchronized non invasive positive pressure ventilation with NAVA

Group Type EXPERIMENTAL

NAVA technology to synchronize NIPPV

Intervention Type DEVICE

Neurally adjust ventilator assist is used to synchronize the NIPPV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NAVA technology to synchronize NIPPV

Neurally adjust ventilator assist is used to synchronize the NIPPV

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Babies born less than 1kg.
2. Babies born at 24-30 weeks gestation.
3. Babies who qualify for surfactant administration within 90mins of birth:

* FiO2 \> 0.4,
* nCPAP \> 6, with
* Increased work of breathing as noted by grunting; and/or inter-, sub-, or supra-sternal retractions.

Exclusion Criteria

1. Babies with Grade 3-4 IVH (may not be known prior to randomization).
2. Babies with congenital anomalies including neuromuscular disorder.
3. Babies who do not require intubation until 7 days of life.
Minimum Eligible Age

24 Weeks

Maximum Eligible Age

30 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

New York Medical College

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lance Parton, MD

Role: PRINCIPAL_INVESTIGATOR

Westchester Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Westchester Medical Center

Valhalla, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Louie K, Amatya S, Alpan G, Parton LA. Non-Invasive Ventilation with Neurally Adjusted Ventilatory Assist (NAVA) Improves Extubation Outcomes in Extremely Low-Birth-Weight Infants. Children (Basel). 2024 Sep 28;11(10):1184. doi: 10.3390/children11101184.

Reference Type DERIVED
PMID: 39457149 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

L12,175

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Non-invasive Ventilation in Preterm Infants
NCT05987800 ACTIVE_NOT_RECRUITING NA